Delivery Order SPE2DR25D1004-SPE2DR26FSWW1
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,211.94 to AmerisourceBergen Drug Corp on December 10, 2025, for the supply of Trelegy Ellipta 200-62.5-25 inhalers (60-count units). This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, with an ultimate completion date of December 11, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for...
- The Defense Logistics Agency awarded a delivery order valued at $11,207.26 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count units) on October 31, 2025, with a completion date of November 3, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency awarded a $11,097.32 delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for Trelegy Ellipta 100-62.5-25 inhalers (60-count supply). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of October 23, 2025, and performance location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order valued at $68,803.32 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count packages) on December 16, 2025, with completion scheduled for December 17, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,076.77 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count supply). This is a firm fixed-price, competitively awarded contract with no set-aside designation, with an ultimate completion date of July 22, 2025. The award was made to AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania, the company's headquarters location, which also serves as the place of performance for...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,554.00 to AmerisourceBergen Drug Corp for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). Issued on June 9, 2025, with an ultimate completion date of June 10, 2025, this firm fixed-price delivery order was competitively awarded with no set-aside designation. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a $31,540.49 delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of May 13, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,725.89 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count packaging), with an ultimate completion date of August 28, 2025. This competitively awarded, firm fixed-price delivery order was issued with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $22,534.20 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count supply). This firm fixed price contract, awarded on August 15, 2025, represents a competitive award with no set-aside designation and will be completed by August 18, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $26,352.03 to AmerisourceBergen Drug Corp for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). This competitively awarded, firm fixed-price delivery order was issued on September 19, 2025, with an ultimate completion date of September 22, 2025. The contract carries no set-aside designation, indicating that AmerisourceBergen competed openly against other qualified vendors. The pharmaceutical product will...
- SPE2DR25D1004Indefinite Delivery Contract
- SPE2DR25D1004-SPE2DR26FSWW1Delivery Order
The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a $1,341.93 delivery order for Trelegy Ellipta 100-62.5-25 inhalers (60-count). This is a firm fixed price, competitively awarded contract with no set-aside designation, with an ultimate completion date of December 22, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. The Trelegy Ellipta product is a combination respiratory medication used in the treatment of chronic obstructive pulmonary disease (COPD) and asthma. AmerisourceBergen's substantial IDC with DLA enables the company to supply a broad range of pharmaceuticals and medical supplies to support Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The company's demonstrated capability to fulfill federal medical procurement requirements through open competition, combined with its extensive portfolio of brand-name and generic medications across multiple therapeutic domains, positions it as a critical vendor for military and veteran healthcare supply chains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 12/18/25 |